Smell test challenge suggests clinical benefit for some before development of Alzheimer's

November 10, 2017
PET scan of a human brain with Alzheimer's disease. Credit: public domain

Researchers at Columbia University Medical Center (CUMC) and the New York State Psychiatric Institute (NYSPI) may have discovered a way to use a patient's sense of smell to treat Alzheimer's disease before it ever develops. Having an impaired sense of smell is recognized as one of the early signs of cognitive decline, before the clinical onset of Alzheimer's disease. The researchers at CUMC and NYSPI have found a way to use that effect to determine if patients with mild cognitive impairment may respond to cholinesterase inhibitor drugs to treat Alzheimer's disease.

The findings were published online this week in the Journal of Alzheimer's Disease.

Cholinesterase inhibitors, such as donepezil, enhance cholinergic function by increasing the transmission of the neurotransmitter acetylcholine in the brain. Cholinergic function is impaired in individuals with Alzheimer's . Cholinesterase inhibitors, which block an enzyme that breaks down acetylcholine, have shown some effectiveness in improving the cognitive symptoms of Alzheimer's disease. However, they have not been proven effective as a treatment for individuals with mild cognitive impairment (MCI), a condition that markedly increases the risk of Alzheimer's disease.

"We know that cholinesterase inhibitors can make a difference for Alzheimer's patients, so we wanted to find out if we could identify patients at risk for Alzheimer's who might also benefit from this treatment," said D.P. Devanand, MBBS, MD, professor of psychiatry, scientist in the Gertrude H. Sergievsky Center at CUMC, and co-director of the Memory Disorders Clinic and the Late Life Depression Clinic at NYSPI. "Since odor identification tests have been shown to predict progression to Alzheimer's, we hypothesized that these tests would also allow us to discover which patients with MCI would be more likely to improve with donepezil treatment."

In this year-long study, 37 participants with MCI underwent odor identification testing with the University of Pennsylvania Smell Identification Test (UPSIT). The test was administered before and after using an atropine nasal spray that blocks cholinergic transmission.

The patients were then treated with donepezil for 52 weeks, and were periodically reevaluated with the UPSIT and with memory and cognitive function tests. Those who had a greater decline in UPSIT scores, indicating greater cholinergic deficits in the brain, after using the anticholinergic nasal spray saw greater cognitive improvement with donepezil.

In addition, short-term improvement in odor identification from baseline to eight weeks tended to predict longer-term cognitive improvement with donepezil treatment over one year.

"These results, particularly if replicated in larger populations, suggest that these simple inexpensive strategies have the potential to improve the selection of with who are likely to benefit from treatment with cholinesterase inhibitors like donepezil," said Dr. Devanand.

Explore further: Alzheimer's drug prescribed 'off-label' for mild cognitive impairment could pose risk for some

More information: D.P. Devanand et al, Change in Odor Identification Impairment is Associated with Improvement with Cholinesterase Inhibitor Treatment in Mild Cognitive Impairment, Journal of Alzheimer's Disease (2017). DOI: 10.3233/JAD-170497

Related Stories

Alzheimer's drug prescribed 'off-label' for mild cognitive impairment could pose risk for some

February 24, 2017
Donepezil, a medication that is approved to treat people with Alzheimer's disease, should not be prescribed for people with mild cognitive impairment without a genetic test. UCLA School of Nursing researchers discovered that ...

Smell test may predict early stages of Alzheimer's disease

July 26, 2016
Researchers from Columbia University Medical Center (CUMC), New York State Psychiatric Institute, and NewYork-Presbyterian reported that an odor identification test may prove useful in predicting cognitive decline and detecting ...

Study ranks safety, effectiveness of cognitive enhancers for Alzheimer's

September 29, 2017
A new study ranking the safety and effectiveness of four drugs taken to enhance concentration, memory, alertness and moods, found that donepezil was most likely to effectively improve cognition in patients with Alzheimer's ...

Could nasal insulin be an effective therapy for Alzheimer's?

March 28, 2017
Can insulin, the hormone used for nearly a century to treat diabetes, improve cognition, memory and daily function in people with mild cognitive impairment or mild dementia due to Alzheimer's disease?

Study confirms 'sniff test' may be useful in diagnosing early Alzheimer's disease

December 20, 2016
Tests that measure the sense of smell may soon become common in neurologists' offices. Scientists have been finding increasing evidence that the sense of smell declines sharply in the early stages of Alzheimer's, and now ...

Recommended for you

Alzheimer's Tau protein forms toxic complexes with cell membranes

November 22, 2017
The brains of patients with Alzheimer's disease contain characteristic tangles inside neurons. These tangles are formed when a protein called Tau aggregates into twisted fibrils. As a result, the neurons' transport systems ...

Researchers reveal new details on aged brain, Alzheimer's and dementia

November 21, 2017
In a comprehensive analysis of samples from 107 aged human brains, researchers at the Allen Institute for Brain Science, UW Medicine and Kaiser Permanente Washington Health Research Institute have discovered details that ...

Dementia study sheds light on how damage spreads through brain

November 20, 2017
Insights into how a key chemical disrupts brain cells in a common type of dementia have been revealed by scientists.

Researchers describe new biology of Alzheimer's disease

November 20, 2017
In a new study, researchers from Boston University School of Medicine (BUSM) describe a unique model for the biology of Alzheimer's disease (AD) which may lead to an entirely novel approach for treating the disease. The findings ...

Study shows video games could cut dementia risk in seniors

November 16, 2017
Could playing video games help keep the brain agile as we age?

New player in Alzheimer's disease pathogenesis identified

November 14, 2017
Scientists at Sanford Burnham Prebys Medical Discovery Institute (SBP) have shown that a protein called membralin is critical for keeping Alzheimer's disease pathology in check. The study, published in Nature Communications, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.